drugset / Trial / NCT05199129

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

NCT05199129

Phase 3 Completed 166 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.

Timeline

Start
2021-11-17
Primary completion
2022-09-14
Completion
2022-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1904-3 Unknown Oral
Subject RLD2001-1 Unknown Oral